OCTAPHARMA
11.1.2021 11:43:28 CET | Business Wire | Press release
Octapharma announced today a satellite symposium and poster presentation at the 14th annual congress of the European Association for Haemophilia and Allied Disorders (EAHAD), which will be held virtually from February 3–5, 2021.
The satellite symposium, A family journey with Nuwiq® : Early treatment decisions for long-term health , will be chaired by Dr Robert F. Sidonio Jr. (Hemophilia of Georgia Center for Bleeding and Clotting Disorders, Children’s Healthcare of Atlanta, Emory University, Atlanta, USA) and will follow the treatment journey of a family with two sons diagnosed with severe haemophilia A. Speakers will address key treatment decisions and considerations for long-term health, including prevention and treatment of bleeds, inhibitor risk, inhibitor eradication, and bone and joint health, in the context of the evolving haemophilia A treatment landscape. The symposium will be available via the EAHAD online platform on February 4, 2021, at 18:00 CET.
In a poster session, Dr Sylvia Horneff (Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Bonn, Germany) will present single-centre experience of bleeding management in 46 patients with acquired haemophilia A, a rare autoimmune disorder, including nine patients treated with octanate® :
Poster ABS193 Safety and efficacy of high-dose, plasma-derived FVIII in patients with acquired haemophilia A (Di Prinzio G et al.)
Larisa Belyanskaya, Head of IBU Haematology at Octapharma, commented that, “We are proud to share real-life experience of the positive impact of Nuwiq® in children with haemophilia A. Alongside clinical trial data across our portfolio, such experience helps to inform treatment decisions, which are increasingly complex as new therapies arise .”
Olaf Walter, Board Member at Octapharma added, “Our ultimate aim at Octapharma is to improve patients’ lives, and seeing our work achieve this goal brings real pride. Our contributions to the EAHAD congress highlight our commitment to enabling people with haemophilia A to lead a long, active and healthy life ”.
About Octapharma
Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Haematology, Immunotherapy, and Critical Care.
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum. In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US.
About Nuwiq®
Nuwiq® (simoctocog alfa) is a 4th generation recombinant factor VIII (rFVIII) protein, produced in a human cell line without chemical modification or fusion with any other protein1 . It is cultured without additives of human or animal origin, is devoid of antigenic non-human protein epitopes and has a high affinity for von Willebrand factor1 . Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 previously treated patients (PTPs; 190 individuals) with severe haemophilia A, including 59 children1 . Nuwiq® is available in 250 IU, 500 IU, 1000 IU, 2000 IU, 2500 IU, 3000 IU and 4000 IU presentations2 . Nuwiq® is approved for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital FVIII deficiency) across all age groups2 .
- Lissitchkov T et al. Ther Adv Hematol 2019; doi: 10.1177/2040620719858471.
- Nuwiq® Summary of Product Characteristics.
About octanate®
octanate® is a human plasma-derived, high-purity, freeze-dried, double virus inactivated factor VIII (FVIII) concentrate for intravenous administration1,2 . FVIII present in octanate® is bound to its natural stabiliser, von Willebrand factor (VWF), in a VWF/FVIII ratio of approximately 0.41 . Therefore, no additional stabilisers are required during manufacturing. octanate® is available in 250 IU, 500 IU and 1000 IU presentations1 . octanate® was first approved over 20 years ago and has since been approved in more than 85 countries for prophylaxis and treatment of bleeding in patients with haemophilia A (congenital FVIII deficiency) of all age groups1 . This preparation is not indicated for von Willebrand’s disease. octanate® is also indicated for immune tolerance induction (ITI) in over 40 countries1 .
- Klukowska A et al. Haemophilia 2018; 24:221-8.
- octanate® Summary of Product Characteristics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005498/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Names Dirk-Jan "DJ" van Hameren Chief Marketing Officer as Member Base Surpasses 3 Million8.7.2026 13:00:00 CEST | Press release
Former Nike Global CMO and two-time Olympian joins WHOOP amid record global acceleration WHOOP, the human performance company, today named Dirk-Jan "DJ" van Hameren as Chief Marketing Officer. The appointment comes as WHOOP surpasses 3 million members worldwide after adding its latest one million members in just seven months. The former Nike Global Chief Marketing Officer and two-time Olympian joins WHOOP to help build the world's defining global brand for human performance and proactive health. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708877245/en/ WHOOP Names Dirk-Jan "DJ" van Hameren (left) Chief Marketing Officer as Member Base Surpasses 3 Million Van Hameren spent more than three decades at Nike, where he rose from the mailroom at the company's European headquarters to become one of the most influential marketing leaders in the world. He served as NIKE Inc.’s Executive Vice President and Chief Marketing Officer
Endace and Artiza Networks Partner to Deliver Cybersecurity and Defense Solutions to the Japanese Market8.7.2026 13:00:00 CEST | Press release
Endace, a leading provider of always-on packet capture, network visibility, and packet forensics solutions, and Artiza Networks, Inc. ("Artiza"), a leading provider of telecommunications test, measurement, and network assurance solutions, today announced a partnership to deliver advanced cybersecurity and defense solutions to customers in Japan. “Artiza is exactly the partner we have been looking for to satisfy demand in Japan, with the right balance of expertise, and market reach,” said Stuart Wilson, CEO of Endace. Through this partnership, Artiza will offer Endace's packet capture, network recording, and packet forensics solutions to customers in Japan, including telecommunications operators, enterprises, government agencies, defense organizations, and critical infrastructure providers. Endace's EndaceProbe Analytics Platform provides highly scalable, always-on packet capture and recording capabilities across a wide range of network environments, including enterprise networks, data
HTEC Introduces “OneLoopAi” Redefining How Enterprises Scale AI Into Production8.7.2026 12:28:00 CEST | Press release
OneLoopAi is the first platform to provide end-to-end transparency between enterprise and partner on AI usage, resource utilization, costs, and value realized. HTEC, the global technology and engineering firm headquartered in Palo Alto, Silicon Valley, today announced it has launched HTEC OneLoopAi—a new platform and approach to managing AI execution and value realization. The platform brings real-time visibility into progress, transparency with customers, and acceleration to how AI is deployed and scaled into production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708166155/en/ HTEC, the global technology and engineering firm headquartered in Palo Alto, Silicon Valley, today announced it has launched HTEC OneLoopAi—a new platform and approach to managing AI execution and value realization. The platform brings real-time visibility into progress, transparency with customers, and acceleration to how AI is deployed and sc
Robbyant Upgrades and Open-Sources LingBot-VLA 2.0 as a Next-Generation Universal Brain for Embodied AI8.7.2026 10:11:00 CEST | Press release
Robbyant, an embodied AI company within Ant Group, today announced the upgrade and open-source release of LingBot-VLA 2.0. Building upon the foundation of LingBot-VLA 1.0 released in January 2026, this next-generation vision-language-action (VLA) model delivers significant leaps in morphological generalization, degrees of freedom (DoF) support, and deployment efficiency, delivering a more advanced “universal brain” for scalable real-world robotics. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707394646/en/ LingBot-VLA 2.0 supports a wide range of robot morphologies While the embodied AI industry is witnessing rapid advancements in hardware and control systems, the lack of a truly universal brain remains a primary bottleneck for industrial-scale deployment. LingBot-VLA 2.0 addresses this critical gap by dramatically expanding its pre-training data and architectural capabilities. LingBot-VLA 2.0 was pre-trained on 60,000
TetraMem and SK hynix Showcase Successful Technology Collaboration Advancing Memory-Centric AI Computing8.7.2026 10:06:00 CEST | Press release
Joint achievement highlights how Analog In-Memory Computing can address the growing energy and thermal challenges of AI while laying the foundation for deeper collaboration on next-generation memory and computing architectures. TetraMem Inc., a leader in Analog In-Memory Computing (A-IMC) technology, and SK hynix Inc., a global leader in AI memory and semiconductor technologies, today announced the successful completion of a joint technology collaboration, highlighted by the publication of their research paper, “A Memristor-based In-Memory Computing SoC with Efficient Depthwise Convolution,” in Advanced Intelligent Systems. The work has also been selected as the cover feature of the journal, recognizing its technical innovation and potential impact on next-generation AI computing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708244132/en/ The collaboration brings together SK hynix’s expertise in advanced memory technolo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom